Hepatoprotective effect of silymarin
Top Cited Papers
Open Access
- 1 January 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 6 (3), 144-9
- https://doi.org/10.4254/wjh.v6.i3.144
Abstract
The use of medicinal plants in treating illnesses has been reported since ancestral times. In the case of hepatic diseases, several species such as Silybum marianum, Phyllanthus niruri, and Panus giganteus (Berk.) have been shown to ameliorate hepatic lesions. Silymarin is a natural compound derived from the species Silybum marianum, which is commonly known as Milk thistle. This plant contains at least seven flavoligands and the flavonoid taxifolin. The hepatoprotective and antioxidant activity of silymarin is caused by its ability to inhibit the free radicals that are produced from the metabolism of toxic substances such as ethanol, acetaminophen, and carbon tetrachloride. The generation of free radicals is known to damage cellular membranes and cause lipoperoxidation. Silymarin enhances hepatic glutathione and may contribute to the antioxidant defense of the liver. It has also been shown that silymarin increases protein synthesis in hepatocytes by stimulating RNA polymerase I activity. A previous study on humans reported that silymarin treatment caused a slight increase in the survival of patients with cirrhotic alcoholism compared with untreated controls.Keywords
This publication has 34 references indexed in Scilit:
- Dual Effects of Silymarin on Nasopharyngeal Carcinoma Cells (NPC-TW01)Complementary Medicine Research, 2013
- Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia–Pacific regionThe Esophagus, 2013
- Silymarin in non alcoholic fatty liver diseaseWorld Journal of Hepatology, 2013
- Hepatoprotective Effects ofPanus giganteus(Berk.) Corner against Thioacetamide- (TAA-) Induced Liver Injury in RatsEvidence-Based Complementary and Alternative Medicine, 2012
- Alcoholic Liver Disease: Pathogenesis and New Therapeutic TargetsGastroenterology, 2011
- Silybin and the liver: From basic research to clinical practiceWorld Journal of Gastroenterology, 2011
- Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis CThe Journal of Clinical Pharmacology, 2010
- Identification of hepatoprotective flavonolignans from silymarinProceedings of the National Academy of Sciences of the United States of America, 2010
- Large-Scale Isolation of Flavonolignans fromSilybum marianumExtract Affords New Minor Constituents and Preliminary Structure-Activity RelationshipsPlanta Medica, 2009
- Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liverJournal of Hepatology, 1989